ASXL1 mutations in idiopathic cytopenias: determined significance?

被引：0

作者：

Galvez, Carlos ^{[1
]}

Stein, Brady L. ^{[2
,3
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA

[2] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 03期

关键词：

CLONAL HEMATOPOIESIS; RISK; ICUS; MDS;

D O I：

10.1080/10428194.2018.1516880

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：568 / 570

页数：3

共 50 条

[31] ASXL1 Mutations Are Associated with Widespread and Distinct DNA Methylation Alterations
Rahmani, Nora E.
Ramachandra, Nandini
Bhagat, Tushar D.
Gordon, Shanisha
Pradhan, Kith
Pena, Bianca Rivera
Kazemi, Mohammad
Giricz, Orsi
Maqbool, Shahina
Olea, Raul
Dolatshad, Hamid
Tittrea, Vickram
Tatwavedi, Dharamveer
Singh, Shalini
Pellagatti, Andrea
Boultwood, Jacqueline
Verma, Amit
BLOOD, 2019, 134
[32] Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex
Balasubramani, Anand
Larjo, Antti
Bassein, Jed A.
Chang, Xing
Hastie, Ryan B.
Togher, Susan M.
Lahdesmaki, Harri
Rao, Anjana
NATURE COMMUNICATIONS, 2015, 6
[33] ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo
Yamamoto, Shohei
Shi, Hui
Chen, Shi
Zhang, Peng
Zhou, Yuan
Xu, Mingjiang
Yang, Feng-Chun
BLOOD, 2015, 126 (23)
[34] Clinical Features of Patients with ASXL1 and ASXL2 Mutations in Pediatric Acute Myeloid Leukemia
Yamato, Genki
Shiba, Norio
Yoshida, Kenichi
Ohki, Kentaro
Park, Myoung-ja
Hara, Yusuke
Tomizawa, Daisuke
Sotomatsu, Manabu
Taga, Takashi
Adachi, Souichi
Tawa, Akio
Horibe, Keizo
Arakawa, Hirokazu
Ogawa, Seishi
Hayashi, Yasuhide
BLOOD, 2014, 124 (21)
[35] Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone
Song, Jinming
Moscinski, Lynn C.
Yang, Ethan
Hussaini, Mohammad
Zhang, Hailing
BLOOD, 2022, 140 : 4026 - 4027
[36] ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics
Kakosaiou, Katerina
Panitsas, Fotios
Daraki, Aggeliki
Pagoni, Maria
Apostolou, Paraskevi
Ioannidou, Agapi
Vlachadami, Ioanna
Marinakis, Theodoros
Giatra, Chara
Vasilatou, Diamantina
Sambani, Constantina
Pappa, Vassiliki
Manola, Kalliopi N.
LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2439 - 2446
[37] Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
A Tefferi
T L Lasho
C Finke
N Gangat
C A Hanson
R P Ketterling
A Pardanani
Leukemia, 2018, 32 : 837 - 839
[38] Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
Tefferi, A.
Lasho, T. L.
Finke, C.
Gangat, N.
Hanson, C. A.
Ketterling, R. P.
Pardanani, A.
LEUKEMIA, 2018, 32 (03) : 837 - 839
[39] Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)
Duployez, Nicolas
Micol, Jean-Baptiste
Boissel, Nicolas
Petit, Arnaud
Geffroy, Sandrine
Bucci, Maxime
Lapillonne, Helene
Renneville, Aline
Leverger, Guy
Ifrah, Norbert
Dombret, Herve
Abdel-Wahab, Omar
Jourdan, Eric
Preudhomme, Claude
LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 199 - 200
[40] Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
Yan, Xin
Xu, Zefeng
Zhang, Peihong
Sun, Qi
Jia, Yujiao
Qin, Tiejun
Qu, Shiqiang
Pan, Lijuan
Li, Zhanqi
Liu, Jinqin
Song, Zhen
Gao, Qingyan
Jiao, Meng
Gong, Jingye
Wang, Huijun
Li, Bing
Xiao, Zhijian
BLOOD CANCER JOURNAL, 2023, 13 (01)

← 1 2 3 4 5 →